| DC Field | Value | Language |
|---|
| dc.contributor.author | Petrovsky, A. K. | - |
| dc.contributor.author | Smirnov, N. A. | - |
| dc.contributor.author | Vdovichenko, V. P. | - |
| dc.contributor.author | Fedorova, T. B. | - |
| dc.contributor.author | Kerbenev, E. E. | - |
| dc.date.accessioned | 2022-04-24T12:59:17Z | - |
| dc.date.available | 2022-04-24T12:59:17Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis / A.K. Petrovsky [et al.] // Research Results in Pharmacology. - 2019. - Vol. 5, № 4.- P. 33-39. - Doi: 10.3897/rrpharmacology.5.38769. - Refer.: p. 38-39. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46324 | - |
| dc.description.abstract | The article notes that administering selank and semax to patients with tuberculosis would significantly reduce the number and severity of hepatotoxic reactions | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | tuberculosis | ru |
| dc.subject | hepatoprotection | ru |
| dc.subject | hepatoprotector | ru |
| dc.subject | drug-induced liver lesions | ru |
| dc.subject | semax | ru |
| dc.subject | selank | ru |
| dc.title | Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 5, № 4
|
